Search the Newsreel

MapLight dives despite positive data for schizophrenia drug

MapLight Therapeutics shares fell by 66% after releasing Phase 2 study results for a schizophrenia drug, despite the data showing positive results regarding general safety and efficacy. Investors were reportedly concerned that the drug's efficacy profile would not be competitive with Bristol Myers Squibb's …

MapLight Therapeutics Says Phase 2 Schizophrenia Trial Meets Primary Endpoint

MapLight Therapeutics announced that its Phase 2 trial for a new schizophrenia treatment successfully met its primary endpoint. This positive outcome indicates potential progress in developing novel therapies for schizophrenia, building on the company's research efforts.

MapLight Reports Results From Phase 2 ZEPHYR Trial Of ML-007C-MA; Stock Down More Than 60%

(RTTNews) - MapLight Therapeutics (MPLT) announced positive topline results from its Phase 2 ZEPHYR trial evaluating ML-007C-MA in adults with an acute exacerbation of schizophrenia. The trial met its primary endpoint, with the 210/3 mg twice-daily dose demonstrating a statistically significant and clinically meaningful …

MapLight Therapeutics stock tumbles 50% on mixed phase 2 schizophrenia data (MPLT:NASDAQ)

MapLight Therapeutics (MPLT) stock dropped 50% in premarket trading despite positive Phase 2 trial results for its schizophrenia drug candidate. The decline was due to the once-daily dosing regimen failing to achieve statistical significance on the primary endpoint, although the trial did meet its …

MapLight Therapeutics Announces Positive Topline Results from Phase 2 ZEPHYR Trial of ML-007C-MA in Schizophrenia

MapLight Therapeutics announced positive topline results from its Phase 2 ZEPHYR trial for ML-007C-MA in schizophrenia, meeting its primary endpoint with a statistically significant improvement in PANSS total score at the 210/3 mg BID dose. The trial also showed significant improvements in cognitive performance …

MapLight Therapeutics (Nasdaq: MPLT) hits key Phase 2 goal in schizophrenia

MapLight Therapeutics announced positive topline results for its Phase 2 ZEPHYR trial of ML-007C-MA in adults with acute exacerbation of schizophrenia. The 210/3 mg twice-daily dose met the primary endpoint with a statistically significant reduction in PANSS total score and showed clinically meaningful improvement …

MapLight Therapeutics Inc (MPLT) Cash Flow

This article provides MapLight Therapeutics Inc (MPLT) cash flow statement data for FY2026Q1, including operating, investing, and financing cash flows. It breaks down key financial metrics, such as a -51.18M operating cash flow and a 67.01M investing cash flow, and offers FAQs explaining cash …

MPLT|MapLight Therapeutics Inc|Price:11.550|Chg%:-0.030

MPLT|MapLight Therapeutics Inc|Price:11.980|Chg%:-0.200

MPLT Stock Plunges 73% — Wipes Out Over $1B In Market Cap After Trial Miss On Once-Daily Dose

MapLight Therapeutics (MPLT) Rally Puts Its CNS Story And Valuation In Focus

MapLight Therapeutics (MPLT) has experienced a significant rally in 2024, with its share price up 118.01% year-to-date, drawing attention to its clinical-stage central nervous system pipeline. Currently trading at $36.56 with a market value of $1.66 billion, the stock's price-to-book ratio of 4.1x is …

MapLight Therapeutics, Inc. Revenue Breakdown – NASDAQ:MPLT

This article provides a company overview for MapLight Therapeutics, Inc. (MPLT) on the NASDAQ, focusing on its financial data. It covers various fundamental and statistical aspects, including statements, dividends, earnings, and segments, while noting that market data is provided by ICE Data Services and …

Is MapLight Therapeutics (MPLT) Fully Valued As Its Shares Hold Near $36.56?

MapLight Therapeutics (MPLT) shares have seen significant gains recently, with a year-to-date return of 118.01%, bringing its stock price to $36.56. The company currently trades at a Price-to-Book (P/B) ratio of 4.1x, which is higher than its peer average of 3.5x and the broader …

Canaccord raises MapLight Therapeutics price target on trial data By Investing.com

Canaccord has increased its price target for MapLight Therapeutics (NASDAQ: MPLT) to $43 from $35, maintaining a Buy rating, ahead of top-line data from its Phase 2 ZEPHYR trial for ML-007C-MA in mid-August 2026. Other firms like UBS, Needham, and Raymond James have also …

Possible Bearish Signals With MapLight Therapeutics Insiders Disposing Stock

Insiders at MapLight Therapeutics (NASDAQ: MPLT) have sold a significant amount of stock over the past year, totaling US$6.3 million, compared to US$694k in purchases. The recent insider selling, particularly US$3.8 million worth of shares dumped in the last three months with no corresponding …

MapLight Therapeutics general counsel sells $607,870 in shares

MapLight Therapeutics General Counsel Kristopher Hanson sold $607,870 worth of company stock between July 15 and July 17, 2026. These sales were not discretionary but rather "sell to cover" transactions to satisfy tax obligations from restricted stock unit vesting. The company has also recently …

Maplight Therapeutics (NASDAQ:MPLT) Upgraded by BMO Capital Markets to Strong-Buy Rating

BMO Capital Markets upgraded Maplight Therapeutics (NASDAQ:MPLT) to a "strong-buy" rating. This upgrade follows several other analysts' reports, resulting in the company currently holding an average "Buy" rating and a price target of $40.09. The article also details recent insider selling activity and institutional …

BMO Capital Maintains MapLight Therapeutics(MPLT.US) With Buy Rating, Maintains Target Price $46

BMO Capital has reiterated its Buy rating for MapLight Therapeutics (MPLT.US) and maintained its price target of $46. This reflects the firm's continued positive outlook on the company's stock performance.

UBS Adjusts MapLight Therapeutics Price Target to $52 From $48, Maintains Buy Rating

UBS has increased its price target for MapLight Therapeutics to $52 from $48, while reaffirming its Buy rating on the stock. This adjustment suggests a positive outlook from UBS regarding the pharmaceutical company's future performance.

MapLight Therapeutics CEO Kroeger sells $5.4m in company stock

MapLight Therapeutics CEO Christopher A. Kroeger sold 147,639 shares of company stock for approximately $5.4 million to cover tax withholding obligations related to restricted stock units. This was a "sell to cover" transaction, not a discretionary sale. The company has also received positive analyst …

MapLight Therapeutics (MPLT) CDO sells 36K shares via tax and plan trades

Anatol Kreitzer, Chief Discovery Officer of MapLight Therapeutics (MPLT), sold a total of 36,284 shares of Voting Common Stock between July 15 and July 17, 2026. These sales occurred at weighted-average prices ranging from $35.68 to $38.21 per share. The transactions included "sell to …

MapLight Therapeutics (MPLT) CAO and interim CFO reports 36,979-share stock sale

Jonathan Gillis, CAO and interim CFO of MapLight Therapeutics (MPLT), reported selling 36,979 shares of Voting Common Stock between July 15-17, 2026. These sales, valued at approximately $1.37 million, occurred at weighted-average prices ranging from $35.68 to $38.37 per share. Some transactions were "sell …

Maplight Therapeutics (MPLT) holder files to sell 48,158 shares via Jefferies

A Maplight Therapeutics holder, Erin Pennock Foff, has filed to sell 48,158 common shares through Jefferies LLC, with an indicated sale date of July 15, 2026. These shares have an aggregate market value of $1,825,669.78. The seller acquired these shares through restricted stock unit …

Maplight Therapeutics (MPLT) logs planned and recent common stock sales

Maplight Therapeutics (MPLT) has filed a Form 144 notice detailing planned and recent common stock sales. The filing indicates the issuance of restricted stock unit grants on several dates and includes sales by Kris Hanson over the past three months. Jefferies LLC is also …

MapLight Therapeutics (MPLT) CMO reports 47,158-share stock sale

MapLight Therapeutics, Inc.'s Chief Medical Officer, Erin Pennock Foff, sold a total of 47,158 shares of Voting Common Stock between July 15 and July 17, 2026. These transactions included sales made under a Rule 10b5-1 trading plan adopted in December 2025 and "sell to …

MapLight Therapeutics CSO Lillie James Woodruff sells $673K in shares By Investing.com

Lillie James Woodruff, CSO of MapLight Therapeutics (NASDAQ:MPLT), sold shares worth $673,636 to cover tax withholding obligations related to restricted stock units. Despite this "sell to cover" transaction, which is mandatory under company equity plans, MapLight Therapeutics has recently received positive analyst coverage and …

Form 144 MapLight Therapeutics For: 17 July By Investing.com

This article from Investing.com announces the filing of Form 144 for MapLight Therapeutics on July 17. Form 144 indicates an insider's intent to sell restricted or control securities. The brief notice provides the company name and date of the filing.

MapLight Therapeutics CMO sells $1.73m in stock

Erin Pennock Foff, CMO of MapLight Therapeutics (NASDAQ: MPLT), sold approximately $1.73 million worth of company stock between July 15 and July 17, 2026. A significant portion of these sales was to cover tax withholding obligations related to restricted stock units, with some shares …

MapLight Therapeutics Insiders Sold Shares Worth Over $6.7M

Insiders at MapLight Therapeutics, including the CEO, CSO, and General Counsel, sold voting common stock between July 15-17, 2026. The total value of shares sold exceeded $6.7 million, with CEO Christopher A. Kroeger accounting for over $5.4 million of the sales. Following these transactions, …

MapLight Therapeutics, Inc. Rings the Nasdaq Stock Market Closing Bell

Maplight Therapeutics (MPLT) Stock Price, News & Analysis

MapLight Therapeutics (MPLT) Stock News